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patients, preoperative radiotherapy appears to be a good 
option for breast conserving therapy.  
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Purpose/Objective: There is a strong inverse association 
between the proliferation indices of early- and late-
responding normal tissues and their sensitivity to 
radiotherapy fraction size. The aim of this study is to test for 
association between Ki67 index and the fractionation 
sensitivity of breast cancer. The hypothesis is that tumours 
with high Ki67 indices are relatively insensitive to fraction 
size and over-represented in tumours relapsing after 
hypofractionated radiotherapy.  
Materials and Methods: Between 1986 and 2003, the START-
P and START-A trials each tested 2 test dose levels of a 13-
fraction regimen (3.0 vs 3.3 Gy & 3.0 vs 3.2 Gy fractions, 
respectively) in 5 weeks against 25 fractions of 2.0 Gy 
following primary surgery for early breast cancer. Primary 
tumour blocks of patients with local tumour relapse were 
collected for immunohistochemistry (IHC) for Ki67, HER2, ER, 
PR, CK5/6, EGFR, Geminin, Cyclin A, ATM, BRCA, PTEN and 
p53. A novel image-processing algorithm was developed to 
enable in silico alignment of serial tumor sections on a pixel-
level and subsequent automated Ki67 scoring. For the initial 
Ki67 assessment all relapsed patients in the test arms were 
grouped together.  
Results: From a total of 3646 patients entered into the 
START-P & -A trials, 261 local tumour relapses were recorded 
at a median follow up of 8.4 years (range 0.9-17.5) and 7.2 
years (range 0.7-11.9), respectively. Blocks from 213 patients 
were recovered, of which 181 were evaluable by IHC. There 
was no significant difference in proliferation between 
tumours relapsing after conventional and hypofractionated 
radiotherapy, with mean Ki67 scores of 7.63 (95%CI: 5.06-
11.5) and 5.33 (95CI%: 3.86-7.35), respectively. There was a 
positive correlation between Ki67 and Geminin scores 
(r=0.43, 95%CI 0.30-0.54, p<0.0001). The ongoing automated 
Ki67 scoring done in 41 patients so far has shown a high 
degree of correlation with manual scoring (r=0.76, 95%CI 
0.60-0.6, p<0.0001). Based on unsupervised hierarchical 
clustering analysisof biomarker expression (binarised data) 
patients were grouped mainly intoER/PR+, CK5/6 & EGFR+ 
and Ki67 high expressors, recapitulating known breastcancer 
subtypes. However, based on this 12-biomarker profile, a 
subgroup of patients enriched for recurrences in the different 
dose fractionation schedules cannot be identified. 
Conclusions: An association between proliferative indices 
and fractionation sensitivity in breast tumours has not been 
demonstrated in the 2 trials analysed together, and adjusted 
analyses of any imbalances in tumour characteristics between 
trials will be presented.  
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Radiotherapy is an essential part of cancer care. Successive 
studies have shown radiotherapy to be inexpensive and cost-
effective. These studies are difficult to undertake and may 
not be applicable in different countries because of variations 
in work practices, wages and capital costs. A population-
based model of radiotherapy demand and benefits could 
provide an estimate cost effectiveness if it was coupled to 
cost data. It could be updated simply by adding new cost or 
epidemiological data. 
We have developed a model of every indication for 
radiotherapy that has allowed us to estimate that 48% of 
cancer cases in a Australian require radiotherapy at least 
once (http://tinyurl.com/pwkua34). It is possible to adapt 
the model to other countries by substituting the relevant 
proportions of cancer types and even stages for that country. 
The model has been expanded to estimate the number of 
fractions per indication and thus an average of 18 fractions is 
needed per course. We have also estimated the survival and 
local control benefit of radiotherapy at 5 years by tumour 
type. Using Markov modelling it is possible to calculate the 
number of Life Years Gained and thus we can calculate a 
survival benefit per fraction. By costing fractions in different 
countries it will be possible to estimate the cost per life year 
gained.  
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Europe is characterized by its highly heterogeneous 
landscape with different cultures, traditions and languages. 
In the context of cancer care as well, large differences are 
observed in cancer incidence and survival, in economic 
aspects and available resources, in organization and funding 
of health care. Cost accounting and economic evaluation 
models should be developed that allow grasping this 
heterogeneity. 
The ESTRO Health Economics in Radiation Oncology (HERO) 
project wants to provide a blueprint of the European 
radiotherapy landscape from an economical perspective. The 
aim is to support the individual European countries and their 
national radiotherapy societies in developing and sustaining 
an optimal radiotherapy service, in line with evidence-based 
